681249-56-9

Basic information

• Product Name: 2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE
• Synonyms: 2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE;2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A];[1,2,4]Triazolo[1,5-a]pyrazine, 2-(trifluoromethyl)-
• CAS NO: 681249-56-9
• Molecular Formula: C6H3F3N4
• Molecular Weight: 188.11
• Mol File: 681249-56-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.69±0.1 g/cm3(Predicted)
• PKA: -2.12±0.30(Predicted)
• CAS DataBase Reference: 2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE(681249-56-9)
• EPA Substance Registry System: 2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE(681249-56-9)

Safety Data

• Hazardous Substances Data: 681249-56-9(Hazardous Substances Data)

Usage

General Description

2-(Trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyrazine is a chemical compound with the molecular formula C5H2F3N5. It is a heterocyclic compound that contains three nitrogen atoms and three fluorine atoms. 2-(TRIFLUOROMETHYL)-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE has potential applications in pharmaceuticals and agrochemicals due to its unique structure and properties. It may be used as a building block in the synthesis of new drugs and crop protection products. Additionally, it has been identified as a potential scaffold for the development of new chemical entities with biological activity. The compound's specific properties and potential applications make it an interesting target for further research and development in various fields.

Upstream product

• 681249-55-8 C₆H₅F₃N₄O 
• 681249-55-8 2,2,2-trifluoro-N’-hydroxy-N-pyrazin-2-ylacetimidamide 

Downstream Products

• 681249-57-0 2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine 

Relevant articles and documents

Synthesis process of PARP inhibitor fluzopanb intermediate

The invention discloses a process method suitable for large-scale preparation of 2-trifluoromethyl [1,2,4]triazolo[1,5-a] pyrazine, and belongs to the field of drug intermediate synthesis, wherein 2-aminopyrazine and ethyl trifluoroacetate are used as raw materials, and a transesterification reaction, a substitution reaction and a dehydration reaction are performed to obtain 2-trifluoromethyl [1,2,4]triazolo[1,5-a] pyrazine. According to the process disclosed by the invention, cheap ethyl trifluoroacetate is selected to replace expensive trifluoroacetic anhydride, other organic solvents replace a first-class solvent dichloroethane, and TFFA replaces PPA which is difficult to post-treat, so that the production cost of existing biological, medical and chemical intermediates is greatly reduced, amplification verification is conducted on the kilogram-level scale of the process, the yield and the product purity are basically equivalent to those of the gram-level scale, and the process is expected to serve as an industrial large-scale production process.

AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.